ResMed Shares Slip Amid Eli Lilly's FDA Approval
ResMed shares decline after FDA approves Eli Lilly's weight-loss treatment for sleep apnea, impacting the sleep therapy market.
ResMed shares slumped after FDA approved Eli Lilly's weight-loss treatment for sleep apnea.